The drug has now met its endpoints in two Phase III trials. Credit: maxbelchenko / Shutterstock.com Veradermics’ stock was up nearly 6% at market open today after a Phase III trial evaluating its hair ...
Migraine involves recurrent attacks of moderate to severe head pain, frequently accompanied by sensitivity to light and sound. Credit: Tunatura/Shutterstock.com. Merz Therapeutics has concluded ...
Vanda has put the late-stage programme for VQW-765 in SAD on ice at it assesses the full dataset. Credit: omahgrafisgk / Shutterstock.com. Vanda Pharmaceuticals has hit pause on a late-stage programme ...
The trial randomised 274 participants to subcutaneous Taltz or the combination, alongside counselling on diet and physical activity. Credit: Pixel-Shot/Shutterstock.com. Eli Lilly and Company has ...
Recruitment for the trial is set to commence in the third quarter of this year. Credit: Johnstocker Production / Shutterstock.com. The US Food and Drug Administration (FDA) has cleared Caliway ...
Verastem Oncology’s KRAS inhibitor has shown promise in several tumour types, including metastatic pancreatic ductal adenocarcinoma (mPDAC), metastatic colorectal cancer (mCRC), and advanced non-small ...
The trial intends to use the clinical findings to guide the future development of PLT012 across liver disease. Credit: Shidlovski/Shutterstock.com. Pilatus Biosciences has dosed the first patient in ...
Produodopa is an alternative to AbbVie’s own Duodopa. Credit: Michael Vi via Shutterstock. On 9 January 2024, AbbVie announced the launch of Produodopa ...
A major focus of R&D in the Alzheimer’s disease therapeutic space is preventing the accumulation of amyloid beta.
BMS announced data from two pivotal trials, with both showing success. Credit: PixelBiss / Shutterstock.com Bristol Myers Squibb (BMS) has seen success in two pivotal trials, one in idiopathic ...
Obuprazine functions as a dopamine D2/D3 receptor partial agonist, a 5-HT1A receptor partial agonist, and a 5-HT2A receptor antagonist. Credit: Antonio Marca/Shutterstock.com. Tortugas Neuroscience ...
argenx is already running Phase III trials of Vyvgart in both myositis and Sjögren’s. Credit: Sheldon Cooper/SOPA Images/LightRocket via Getty Images Argenx’s Vyvgart (efgartigimod alfa-fcab) shows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results